摘要
慢性肺原性心脏病２８例（男性１９例，女性９例；年龄５６±９ａ）采用心脑舒通１３５ｍｇ／ｄ共２ｗｋ，后改为９０ｍｇ／ｄ，维持用药，另设２０例为对照组（男性１３例，女性７例；年龄５４±８ａ）除未用心脑舒通外，对症治疗（如头孢拉啶、阿米卡星、氨茶碱、沙丁胺醇等）与心脑舒通组相同。结果：心脑舒通组总有效率为９３％，优于对照组７５％（Ｐ＜０．０５），未见明显不良反应。
Forty-eight patients with chronic pulmonary heart disease(CPHD)were given heterotherapy,among whom 28 patients(M 19,F9;age 56±9 a) were,while 20 control patients(M 13,F 7;age 54±8 a)were not,supplemented with Xin-nao-shu-tong 135 mg/d for 2 wk,then the dosage was naintained at 90 mg/d.Both groups received the same heterotherapy(cefradine or amikacin,aminophylline or salbutamol,etc).Results showed that the total response rate 93% of Xin-nao-shu-tong group was superior to the control group(75%),P<0.05,and adverse reactions were not seen.
出处
《新药与临床》
CSCD
北大核心
1994年第1期43-45,共3页
关键词
心脑舒通
备注粘度
肺心病
皂甙类
Xin-nao-shu-tong
blood viscosity
pulmonary heart disease
saponins
Tribulus terrestris.
